L’Oréal announced today a new partnership with Clue, the period tracking app with 12 million users in 190 countries, and a leader in Femtech, to deepen knowledge on the relationship between skin health and the menstrual cycle.
This collaboration bridges L’Oréal’s historic skincare expertise and beauty-tech ambitions with Clue’s leadership in reproductive health and data-driven technology. In addition, Clue will work with L’Oréal’s Active Cosmetic Division and its clinical experts to develop scientifically informed new content about the menstrual cycle and skin health for Clue’s reproductive health encyclopedia on Helloclue.com.
“We are excited to enter this strategic partnership with Clue, a world leader in the Femtech and Digital Health space. At L’Oréal we have a strong belief that the innovation that we bring to enhance people’s beauty and wellbeing lies at the intersection of science and technology to meet consumers’ expectations and needs. Through this partnership, we want to pioneer…
scientific innovation.
Our goal is to develop the best personalized skincare routines for consumers of all ages regarding skin health, beauty and wellness aspirations, taking into account their menstrual cycles from puberty to menopause,” says Barbara Lavernos, Deputy CEO, in charge of Research, Innovation, and Technology at L’Oréal.
“Our division is a close partner of leading clinical experts around the world.
We are thrilled to join forces with Clue and bring dermatologists, endocrinologists and gynecologists together to increase knowledge on skin issues linked to hormonal cycles, in order to better understand women’s needs and help them to have a healthier skin,” says Myriam CohenWelgryn, President Active Cosmetics Division at L’Oréal…
Members-only article
Unlock the rest of this story
Join free to keep reading RetailBoss beauty coverage, industry analysis, and market intelligence.
- Full article access
- Industry analysis
- Free account
Free access. No credit card required. Your account is created after you verify your email.
Discussion
0 Comments
No comments yet
Start the conversation
Share your take on this story and help shape the discussion.
Sign in to join the discussion.